TrialCancer medicine2024

Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).

Hiroyuki Arai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.